PROVECTUS BIOPHARMACEUTICALS, INC. (symbol: PVCT) is the issuer of record for a Form 4 filing submitted to the SEC.
PROVECTUS BIOPHARMACEUTICALS, INC. (symbol: PVCT) is the issuer of record for a Form 4 filing submitted to the SEC.
PROVECTUS BIOPHARMACEUTICALS, INC. (symbol: PVCT) is the issuer of record for a Form 4 filing submitted to the SEC.
For PROVECTUS BIOPHARMACEUTICALS, INC. (PVCT), CEO and director Edward Pershing reported derivative conversions involving a 2025 8% unsecured convertible promissory note and Series D-1 Convertible Preferred Stock. On August 26, 2026 the 2025 Note automatically converted into 11,328 Series D-1 shares at $2.862 per share, and those preferred shares were then converted into 113,280 common shares, reflecting a 10-for-1 conversion ratio. The reported post-transaction holdings of 2,924,949 common shares and related derivative amounts include corrections to typographical errors in a prior Form 4 and those adjustments themselves do not represent new transactions.
Provectus Biopharmaceuticals reported a net loss of $988,716 for the quarter and $2,289,665 for the six months ended June 30, 2026, both markedly lower than the prior-year periods as operating expenses declined. Research and development spending fell sharply, mainly from reduced clinical and manufacturing activity, while general and administrative costs also decreased on lower professional fees, payroll, legal and stock-based compensation.
Cash increased to $1,156,915 from $251,291 at year-end 2025, helped by $1,695,000 of new 2025 convertible notes and $75,000 raised at majority-owned subsidiary VisiRose, but the company still had a working capital deficit of $6,338,261 and an accumulated deficit of $265,126,832. Management disclosed that these conditions raise substantial doubt about the company’s ability to continue as a going concern and stated that continued operations depend on successfully developing its RBS-based drug candidates and raising additional capital, including through its 2025 Financing convertible note program.
An amended beneficial ownership report states that Edward Pershing, Chairman and CEO of Provectus Biopharmaceuticals, Inc., beneficially owns 52,441,275 shares of common stock, representing 11.61% of the company’s common shares. The percentage is based on 420,279,879 shares outstanding as of June 30, 2026 plus shares underlying his options, preferred stock and convertible notes.
Pershing’s position includes directly held stock, retirement plan holdings, 16,980,144 stock options exercisable within 60 days, and common shares issuable from Series D‑1 convertible preferred and remaining notes. The issuer has issued to him an aggregate $7,512,500 principal amount of secured convertible promissory notes since 2018; $6,642,500 has converted into Series D‑1 preferred at $2.862 per share, including recent automatic conversions in May and June 2026 and a new $15,000 note purchase on May 28, 2026.
PROVECTUS BIOPHARMACEUTICALS, INC. director and CEO Edward Pershing filed an updated Form 4 that corrects a past reporting error rather than recording a new transaction. The filing adjusts his reported holdings of Series D-1 Convertible Preferred Stock, with the footnote stating the change "does not reflect a transaction."
After this correction, Pershing is shown holding 2,866,761 shares of Series D-1 Convertible Preferred Stock. Each preferred share is convertible into 10 shares of common stock and will automatically convert into common stock on December 31, 2028, unless converted earlier under the certificate of designation terms.
PROVECTUS BIOPHARMACEUTICALS, INC. reported that President and director Dominic Rodrigues received a grant of 45,860 shares of Series D-1 Convertible Preferred Stock at a price of $0.00 per share. Each preferred share is convertible into 10 shares of common stock, representing 458,600 underlying common shares. After this grant, Rodrigues holds 1,383,736 shares of Series D-1 Preferred Stock, which will automatically convert into common stock on December 31, 2028 unless converted earlier under the series’ terms.
PROVECTUS BIOPHARMACEUTICALS, INC. director John Lacey III reported receiving a grant of 48,917 shares of Series D-1 Convertible Preferred Stock on June 30, 2026. The shares were awarded at a price of $0.00 per share as a compensation-related acquisition.
Each Series D-1 share is convertible into 10 shares of common stock, representing 489,170 underlying common shares for this grant. After this award, Lacey holds 228,509 shares of Series D-1 Convertible Preferred Stock. The Series D-1 preferred will automatically convert into common stock on December 31, 2028, unless converted earlier under its certificate of designation.
Provectus Biopharmaceuticals director Bailey Webster received a grant of 48,917 shares of Series D-1 Convertible Preferred Stock. The shares were acquired on June 30, 2026 at a stated price of $0.00 per share as a grant or award, not an open-market transaction.
Each share of Series D-1 Preferred Stock is convertible into 10 shares of Provectus common stock. The Series D-1 Preferred Stock will automatically convert into common stock on December 31, 2028, unless converted earlier under the terms of its Certificate of Designation. Following this grant, Webster directly holds 207,535 shares of Series D-1 Preferred Stock.